These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29632054)

  • 1. Biallelic
    Maroto P; Anguera G; Roldan-Romero JM; Apellániz-Ruiz M; Algaba F; Boonman J; Nellist M; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2018 Apr; 16(4):352-358. PubMed ID: 29632054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
    Alsidawi S; Kasi PM
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
    Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
    Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
    Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
    Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
    BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.
    Potter SL; Venkatramani R; Wenderfer S; Graham BH; Vasudevan SA; Sher A; Wu H; Wheeler DA; Yang Y; Eng CM; Gibbs RA; Roy A; Plon SE; Parsons DW
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27748010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 10. A Renal Cell Carcinoma with Biallelic Somatic TSC2 Mutation: Clinical Study and Literature Review.
    Pang J; Wang L; Xu J; Xie Q; Liu Q; Tong D; Liu G; Huang Y; Yang X; Pan J; Yan X; Ma Q; Zhang D; Jiang J
    Urology; 2019 Nov; 133():96-102. PubMed ID: 31454656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract]   [Full Text] [Related]  

  • 12. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study.
    Jacob LA; Shafi G
    Indian J Cancer; 2019; 56(3):274-275. PubMed ID: 31389395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.
    Venugopal B; Ansari J; Aitchison M; Tho LM; Campbell R; Jones RJ
    BMC Urol; 2013 May; 13():26. PubMed ID: 23688003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
    Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
    Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Paule B; Brion N
    Anticancer Res; 2011 Jan; 31(1):331-3. PubMed ID: 21273619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nontuberculous mycobacterial infection after therapy with temsirolimus for metastatic renal cell carcinoma.
    Buchler T; Homolka J; Fencl P; Rosova B; Hytych V; Abrahamova J
    Tumori; 2013; 99(4):e159-63. PubMed ID: 24326853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
    Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
    PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.